Bruker BioSciences Corporation to Present at Lehman Brothers Ninth Annual Global Healthcare Conference; Live Webcast on Friday,
March 08 2006 - 5:02PM
Business Wire
Bruker BioSciences Corporation (Nasdaq: BRKR) today announced that
it will join other leading life sciences companies in presenting at
the Lehman Brothers Ninth Annual Global Healthcare Conference now
taking place March 8 through 10 in Miami. Bruker BioSciences
Corporation's President and CEO, Frank H. Laukien, will present an
overview of the Company, including an update on recent
developments, recently-announced product innovations, and
expectations. Dr. Laukien's presentation will be webcast live at
10:45 AM Eastern Time (7:45 AM Pacific Time) on Friday, March 10,
2006 from the Loews Miami Beach Hotel. The webcast can be accessed
on Bruker BioSciences' website at www.bruker-biosciences.com with
playback. ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation,
headquartered in Billerica, Massachusetts, is the publicly traded
parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker
AXS is a leading developer and provider of life science, materials
research and industrial X-ray analysis tools. Bruker Daltonics is a
leading developer and provider of innovative life science tools
based on mass spectrometry. For more information, please visit
www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our annual report on Form 10-K,
our most recent quarterly reports on Form 10-Q and our current
reports on Form 8-K. We disclaim any intent or obligation to update
these forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024